MedTrace Logo

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

NCT02673749 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 377

Last updated 2018-04-04

No results posted yet for this study

Summary

RP-G28 is being investigated for treatment of moderate to severe lactose intolerance and its potential to improve the tolerance of lactose (dairy products).

Conditions

  • Lactose Intolerance

Interventions

DRUG

RP-G28

Study drug taken orally

OTHER

Placebo

Placebo taken orally

Sponsors & Collaborators

  • Ritter Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673749 on ClinicalTrials.gov